Company Intelligence Profile
Koye Pharmaceuticals Private Limited
Koye Pharmaceuticals Pvt Ltd is a Mumbai-headquartered specialty branded-pharma company founded in 2013 by Preetish Mohan Toraskar and Ravindra Yogesh Shenoy.
Last updated 17 August 2026
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
See what AICA knows about Koye Pharmaceuticals
Deeper analysis, financial signals and peer comparisons.
Company Identity
Confirmed| Registered name | Koye Pharmaceuticals Private Limited |
|---|---|
| CIN | U74120MH2013PTC243214 |
| PAN | AAFCK2001H |
| Status | Active |
| Listing | Unlisted (Private Limited, not listed on any stock exchange) |
| Incorporated | 12 May 2013 |
| ROC | RoC-Mumbai |
| Sector (NIC) |
|
| Registered address | SF A-01, Art Guild House, Phoenix Market City Annexe, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070 |
| Authorized capital | ₹46,01,09,310 (~₹46.01 Cr) |
| Paid-up capital | Conflicting: ₹21.58 Cr vs ₹29,19,29,390 / ₹29.19 Cr. Treat ₹21.58 Cr as the better-supported figure; report both, flagged as a source conflict. |
Business Overview
Confirmed- Koye Pharmaceuticals Pvt Ltd is a Mumbai-headquartered specialty branded-pharma company founded in 2013 by Preetish Mohan Toraskar and Ravindra Yogesh Shenoy
- It markets branded formulations (e.g. Coecortt, Coekastle, Coekastle Kid) and OTC/consumer-health products across Speciality Primary Care, Respiratory, Gynaecology/Women's Health, IVF, Cardio-Diabetes, FMCG and Ayurveda segments, distributed pan-India via a field force reported at ~1,250 medical representatives reaching ~80,000 doctors/month (company website, koye.co — self-reported, not independently verified)
- NIC/registry classification: drug formulation & development (manufacturing)
- Source: koye.co/about-us, Tofler, TheCompanyCheck
Directors
Partial / conflictingCurrent board (per TheCompanyCheck, cross-checked against Tofler/Falconebiz):
| Name | DIN | Role | Appointed |
|---|---|---|---|
| Ravindra Yogesh Shenoy | 00410124 | Director | 16 Jul 2013 |
| Preetish Mohan Toraskar | 05299763 | Director | 09 Sep 2013 |
| Vishal Kaushik | 11246169 | Director | 27 Aug 2025 |
GST Registration
Partial / conflicting| GSTIN | State | PAN | Status |
|---|---|---|---|
| 27AAFCK2001H1Z0 | Maharashtra | AAFCK2001H (Tofler; corroborated by GSTIN prefix 27AAFCK2001H1Z0 — confirmed via 2 independent signals) | - |
Primary GSTIN: 27AAFCK2001H1Z0 (Maharashtra) — confirmed via 2 independent aggregator lookups (Piceapp GST-number-search; a separate name-search cross-reference), and PAN portion (AAFCK2001H) matches the PAN reported by Tofler. Home state: Maharashtra. One low-reliability aggregator snippet claimed "14 GST registrations across 13 states" (multi-state GST footprint would be expected for a pan-India pharma distributor) but this count is not independently corroborated — marked partial. Status: not independently confirmed (state portal not fetched, per source-blocklist).
Financials
Partial / conflictingFY2025 (year ended 31 Mar 2025), standalone (entity basis; consolidated/standalone not explicitly labelled by sources):
| Revenue | ₹129.09 Cr / ~₹128.9 Cr.7–4.0% YoY |
|---|---|
| FY2024 revenue | ₹134.2 Cr — single source, partial |
| EBITDA | not obtained (locked behind premium tiers on all fetched sources) |
| PAT | not obtained (locked). Tofler separately showed a "Net Profit Margin: 3.14%" on a metrics dashboard that also showed an oddly specific "-387.6% net worth decline" — internally inconsistent, treated as low-reliability and not used to derive a PAT figure |
| Net worth | not obtained as a reliable confirmed figure — Tofler's dashboard suggested negative reserves (~-₹102.9 Cr) but this single-source, single-fetch figure conflicts with other metrics on the same page and is not corroborated elsewhere |
| Borrowings | not obtained as a confirmed total — Tofler cited ₹444.6 Cr total borrowings; flagged as a conflict, not a confirmed number |
| Employees | ~673 to ~726 — partial, minor variance |
Funding
Partial / conflicting- Inc42: total funding $4.10M across 3 rounds; last round = debt financing, ~Sep–Oct 2020, with BlackSoil Capital as lender/investor.
- Other aggregator snippets (lower confidence, via general web search rather than direct fetch): "$21.8M raised" naming Peak XV Partners and Aries Holdings (Mauritius) as investors; and separately "$14.09M over 4 rounds" naming BlackSoil Capital, Premji Invest and Peak XV Partners.
- Independently confirmed via Aries Holdings' own website (aries-holdings.com/businesses-1/koye-pharma): Koye Pharma is listed as one of Aries Holdings' portfolio businesses (alongside Qure.ai, Thorne HealthTech) — this investor relationship is corroborated by the investor's own site, though the site does not disclose stake size, investment amount or date.
- Net: an investor relationship with Aries Holdings is confirmed; specific round sizes/dates and the BlackSoil/Peak XV Partners/Premji Invest claims are unconfirmed.
Charges / Borrowings
Partial / conflictingReasonably well corroborated on lender identity, less so on exact outstanding amounts:
- Axis Bank Limited — 2 loans, ~₹41.6 Cr; also listed as a key lender by Falconebiz — confirmed lender, amount single-sourced.
- NKGSB Co-Operative Bank Ltd — 2 loans, ~₹56.9 Cr combined — partial.
- TJSB Sahakari Bank Limited — ~₹3.0 Cr; also named by Falconebiz — confirmed lender, amount single-sourced.
- Falconebiz aggregate view: Open charges ₹101.45 Cr; Satisfied (closed) charges ₹149.76 Cr — single source, partial; not reconciled against Tofler's per-lender figures (which sum to ~₹101.5 Cr open, actually consistent with the "open charges" total — treated as roughly corroborating).
Competitors
Partial / conflictingNamed Indian branded/specialty-pharma peers surfaced by search (note: most are materially larger-scale, listed companies vs Koye's ~₹130 Cr private-company revenue — included as sector comparables, not size-matched peers):
- Alkem Laboratories — large-cap, listed, multi-thousand-Cr revenue.
- Mankind Pharma — large-cap, listed, multi-thousand-Cr revenue.
- Cipla — large-cap, listed, global generics major.
- Alembic Pharmaceuticals — large-cap, listed.
- Eris Lifesciences — mid/large-cap, listed, specialty/branded-formulations focus closest in business model to Koye.
- Biological E — large, private/institutional, vaccines & pharma.
No closely size-matched (₹100–150 Cr revenue) private specialty-pharma peer was confidently identified from the sources fetched; competitor set should be treated as directional/sector-level rather than scale-matched.
Frequently Asked Questions
What does Koye Pharmaceuticals Private Limited do?
What is the CIN of Koye Pharmaceuticals Private Limited?
Where is Koye Pharmaceuticals Private Limited registered?
When was Koye Pharmaceuticals Private Limited incorporated?
Explore on Recur Club
Bharat Ke Super Founders
Recur Club's show spotlighting the founders building India's next generation of companies. Watch their stories.
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.